Rezolute (RZLT) said Wednesday that the Independent Data Monitoring Committee has recommended continuing the biotechnology company's late-stage study to treat patients with congenital hyperinsulinism without increasing the sample size.
The study is designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism who have poorly controlled hypoglycemia, the company said.
Rezolute said enrollment for the study is on track to be completed in May, with topline data due in December.
Shares of Rezolute were up 23% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.